A practical reference on PNB-0408: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
The infantry regiments of the division rotated responsibility to conduct the Citizens' Military Training Camps each year at Camp McClellan. The division participated in Fourth Corps Area or Third Army command post exercises in conjunction with other Regular Army, National Guard and Organized Reserve units, but unlike Regular and Guard units, the 82nd Division did not participate as an organized unit in the Fourth Corps Area maneuvers and the Third Army maneuvers of 1938, 1940, and 1941 due to a lack of enlisted personnel and equipment, with the officers and a few enlisted reservists assigned to fill vacant slots in organized units to bring them to war strength for the exercises, with others assigned duties as umpires or support personnel.
These data exclude two major producers: the United States and China. A previous sharp increase was observed in 2004 from $4–$5 to $27/lb. The price was relatively stable during 2004–2010 at about US$30 per pound (in 100 pound lots) but increased to $65/lb in 2011. The consumption in 2010 was divided as follows: metallurgy – 30%, glass manufacturing – 30%, agriculture – 10%, chemicals and pigments – 10%, and electronics – 10%. China is the dominant consumer of selenium at 1,500–2,000 tonnes/year.
== External links == Databases Drug metabolism database Directory of P450-containing Systems Drug metabolism Drug metabolism portal Small Molecule Drug Metabolism "Activation, Metabolic". Medical Subject Headings. National Library of Medicine. MeSH D065767. Retrieved 2026-05-24. "Inactivation, Metabolic". Medical Subject Headings. National Library of Medicine. MeSH D008658. Retrieved 2026-05-24. "Biotransformation". Medical Subject Headings. National Library of Medicine. MeSH D001711. Retrieved 2026-05-24.
For example, In 8th Harsh Environment Mass Spectrometry Workshop, a group of scientists presented their study about utilization of lightweight MS based instrumentation and small Unmanned Aerial Vehicles UAV platforms for in-situ volcanic plume analysis in Turrialba and Arenal volcanoes (Costa Rica). Mini mass spectrometers relying on miniature 18 mm rods transpector quadrupole for mTorr pressure operation, a miniature turbo molecular drag pump and assets like small, multi-parameter battery powered sensor suite MiniGas embedded with micro PC control system, and telemetry system were integrated in an aircraft to acquire 4D image of an erupting volcanic plume.
Sources: en.wikipedia.org
These feature a gate-all-around transistor architecture that reduces power consumption by up to 45%, improves performance by 23% and reduces area by 16% compared to 5 nm. Researchers, health organizations and regulators are discussing, investigating and partly recommending COVID-19 vaccine boosters that mix the original vaccine formulation with Omicron-adjusted parts – such as spike proteins of a specific Omicron subvariant – to better prepare the immune system to recognize a wide variety of variants amid substantial and ongoing immune evasion by Omicron.
=== Pharmacokinetics === LC–MS is widely used in the field of bioanalysis and is specially involved in pharmacokinetic studies of pharmaceuticals. Pharmacokinetic studies are needed to determine how quickly a drug will be cleared from the body organs and the hepatic (liver) blood flow. MS analyzers are useful in these studies because of their shorter analysis time, and higher sensitivity and specificity compared to UV detectors commonly attached to HPLC systems. One major advantage is the use of tandem MS–MS, where the detector may be programmed to select certain ions to fragment. The measured quantity is the sum of molecule fragments chosen by the operator. As long as there are no interferences or ion suppression in LC–MS, the LC separation can be done quite swiftly.
=== Iranian intelligence agencies === The Dutch government and its intelligence service AIVD claim to have "strong evidence" that Iran used Dutch-Moroccan gangsters to eliminate at least two of its "enemies of the state" on foreign soil, but also that it was actively protecting crime bosses by providing them with a safe haven. The Dutch Ministry of Justice suspects that Ridouan Taghi was protected by Iran's secret service, and claim that he received this level of protection from the Iranian government because he was instrumental in helping Iran eliminate one or more of its most wanted "enemies of the state". According to the Dutch authorities he was believed to take frequent trips to Iran on fast private yachts, while he was hiding out in Dubai. After making the over 150 km trip, Taghi allegedly had several safe houses at his disposal. These allegations came after the gangland-style assassination of Ali Motamed, a 56-year-old electrician, who had settled in a rowhouse after coming to the Netherlands as a refugee. He was killed on 15 December 2015, by two hitmen. For a while, investigators couldn't find a clue for a motive behind the killing. Then it became known that "Ali Motamed" was actually Mohammad-Reza Kolahi, a member of the People's Mujahedin of Iran, who, according to Iranian authorities, was the mastermind behind the 1981 bombing of the headquarters of the Islamic Republican Party, killing over 70 officials.
== Honors and awards == 2005 – HUPO Award 2006 – Buchner Medal 2008 – In recognition of his contribution to the field of protein sciences and proteomics the Association of Biomolecular Resource Facilities (ABRF) selected him for the ABRF 2008 Award. 2010 – Herbert A. Sober Lectureship 2010 – Otto Naegeli Prize 2012 – Thomson Medal Award 2014 – he became a member of the German Academy of Sciences Leopoldina. 2015 – ranked #1 on the 2015 list of "most influential people in the analytical sciences" (by the Analytical Scientist) 2018 – Bijvoet Medal of the Bijvoet Center for Biomolecular Research of Utrecht University 2020 – Marcel Benoist Prize 2026 – Canada Gairdner International Award
=== Pharmacokinetics === The drug is orally active, in contrast to the poor oral bioavailability of ketamine. Its oral bioavailability is >60%. The time to peak levels of blixeprodil is 1.5 hours and its elimination half-life is 4.3 hours.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.